Business Context and Reporting Period
This Form 8-K Current Report was filed by UnitedHealth Group Incorporated on November 18, 2025. The filing reports a corporate governance event rather than financial performance results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a board appointment and contains no financial data.
Material Changes
The material change reported is the appointment of Scott Gottlieb, M.D. as an independent director of the Company, effective immediately on November 18, 2025. Dr. Gottlieb has not yet been appointed to any specific Board committees.
Management Commentary and Background
- Background: Dr. Gottlieb previously served as FDA Commissioner (2017–2019), focusing on transparency, patient safety, and regulatory modernization. He has also held roles at the Centers for Medicare & Medicaid Services and the Federal Health Information Technology Policy Committee.
- Current Roles: He serves as a director for Pfizer, Inc., Tempus AI, Inc., and Illumina, Inc., and is a senior fellow at the American Enterprise Institute.
- Compensation: Dr. Gottlieb will receive compensation in accordance with the Company's standard program for non-employee directors, as detailed in the 2025 proxy statement.
- Indemnification: The Company entered into a standard indemnification agreement with Dr. Gottlieb.
Investor Verification Checklist
- Verify the full text of the Company's 2025 proxy statement for specific director compensation terms.
- Review the standard form of Indemnification Agreement (referenced as Exhibit 10.1 to a July 1, 2015 filing) for liability details.
- Monitor future filings for Dr. Gottlieb's assignment to specific Board committees.
- Confirm no undisclosed material interests in transactions pursuant to Item 404(a) of Regulation S-K.